I am Meenakshi. I live in the buzzing city of Pune (India). I am 39 years right now and completely healthy. Let me take you back in time, the year 2016; My 36th birthday celebration was still on, both at home and hospital. I work as a part-time therapist in a non-profit hospital. All my patients gathered to celebrate my birthday, and this really touched me. At home, my husband and my 3-year-old boy had baked a not-so-good-looking, but love-filled cake. I was thrilled, and it was the best way I could turn 36.
The next morning, while in the shower, I felt a lump in my breast. I assumed I was imagining it and was worrying for no reason. I ignored it for a few days and continued with my daily commitments.
After a long day at work, I was getting ready to go to bed when I felt the lump again. Now, it was almost a week, and I could feel the lump every day. I decided to ask Dr. Sushma, the GP in the OPD at my hospital. Dr. Sushma hesitated a bit after checking me. This got me extremely anxious and worried. She said, “I am not too sure, I think you should get a scan done’’, I looked at her with a curious eye and asked, “You mean, it might be cancer?” She quickly gathered herself and shrugged, “I am not sure, I think it’s better to get a test done before concluding anything.”
I was diagnosed with Stage 1 breast cancer. And, the only thing my oncologist told me, “Don’t be worried. You should be happy you got it checked so early. Early detection is really a plus. The cancer is at a stage when it can be treated, and you can be back to your regular normal life.”
I think this is what stuck to me the most. It’s a normal ailment that can be cured and I am going to work towards making that happen. This attitude of mine along with family support made me strong and we were ready to overcome everything that came our way.
A few weeks later, came the turning point of my life. The tumor was surgically removed. Dr. Priya, my oncologist suggested to take up CanAssist Breast test to find out the breast cancer recurrence risk before going ahead with the treatment.
CanAssist Breast provided additional information about my tumor. The test results helped us to identify the likelihood of cancer returning to a distant site after surgery. Luckily, I was under the low-risk recurrence zone and I was spared from chemotherapy and its side-effects. This timely action of mine not only saved the cost of treatment but also helped me in leading a quality life.
Today, being a breast cancer survivor, I thank OncoStem and Dr. Manjiri for helping me take the most important and timely decision of my life. The decision to take CanAssistBreast test helped me in personalizing my treatment and leading a normal life.
What comes to your mind when you think about breast cancer? It would most probably be ‘chemotherapy,’ ‘fear of a long process of treatment,’ ‘high costs,’ the fear of cancer coming back, and so on. These thoughts can be controlled with the right knowledge and right breast cancer treatments.
Researchers and oncologists have made new and promising forms of treatment for breast cancer. It’s time to personalize your treatment!
Our test classiﬁes patients as ‘low-risk’ or ‘high-risk’ based on the patient’s breast cancer recurrence risks over five years. The clear-cut test result provides doctors with additional information that can be used for treatment planning.
CanAssist Breast is a test that helps to plan the ideal treatment by predicting the breast cancer recurrence risk within five years of surgery. The risk of recurrence is lesser in early-stage breast cancer (Stage 1 and Stage 2), and hence, it is important for doctors and the patients to plan out a suitable course of treatment based on the breast cancer recurrence risk score.
Until a few years back, oncologists and clinicians were deciding cancer treatments based on age, tumor size, node status, grade, ER, PR and HER2 status. OncoStem realized there was a gap in the decision-making paradigm and understanding the tumor biology to comprehend the cancer progression and its aggressiveness would significantly change treatments depending on an individual’s tumor biology.
Tests similar to CanAssist Breast have been based on genomic analysis, whereas CanAssist Breast involves proteomics analysis. The genomics method considers genes of interest in the genome of a cell, whereas CanAssist Breast’s proteomics technique studies the proteins of interest produced by the cell. A 5-year study by OncoStem Diagnostics, recently published online, explains the detailed analysis and results that lead to the test, CanAssist Breast.
Your tumor is different, just like you are, as an individual.
Doctors and oncologists have to know as much possible about your tumor for optimal and ideal treatment.
Artificial intelligence and machine learning is an emerging approach in the healthcare sector including the treatment of breast cancer. CanAssist Breast is the first such test developed in India, specifically for Indian patients. It determines the tumor’s biochemical fingerprint and assesses its aggressiveness. Assessing the tumor biology in detail, the test considers five key biomarkers that are involved in recurrence-related pathways in the cell. Based on this combined analysis performed by proteomics-based technology, the information is then assessed by a statistical algorithm that provides a score between 0 and 100 – whether the patient is at low-risk or high-risk for cancer recurrence. A ‘CAB risk score’ less than 15.5 indicates a low-risk. Depending on each patient’s unique CAB risk score, the doctors can thus plan an ideal treatment tailored to an individual’s patient.
A decision that doctors and patients must make:
‘Fear’ is the most shared and challenging emotion that cancer brings with it. However, fearful a patient might be; it is essential for the patients to know and consider that their treatment can be different from that of the other patients.
Knowing who is eligible for the CanAssist-Breast test can help both patients and doctors. ‘
The patients must meet the below criteria to take CanAssist Breast:
- Patients with early-stage, invasive breast cancer
- Patients with hormone receptor-positive (“ER+ and/or PR+”) and HER2- negative disease
- Lymph node-negative or up to 3 lymph node-positive
- Patients should not have gone through neo-adjuvant chemotherapy
In India alone, 150,000 women are diagnosed with breast cancer every year. Of these, around 50 percent fall in the early-stage breast cancer category and a majority of them are eligible for this test.
Take your decision together
If you or someone among your friends or family are going through breast cancer (early-stage), you must consider taking CanAssist Breast before starting the treatment. If you are an oncologist or a doctor, maybe your patients could avoid the unnecessary treatments and the side effects most usually associated with chemotherapy.
Doctors must suggest the test to their eligible patients and patients must ask their doctors about the test score and personalize their treatment accordingly.
Want to know more about CanAssist Breast? Get in touch with us.